AACR: New platform uses machine learning to predict responses in patients with lung cancer

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC). If clinically validated, it could give clinicians much-needed insight into one of the most pressing challenges in oncology.